Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases - Top-Institutions - MDSpire

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

  • By

  • Dagna Constenla

  • Germain Lonnet

  • Emmanuel Aris

  • Ramsanjay Rk

  • Nathalie Servotte

  • Agnes Mwakingwe-Omari

  • Hannah Alsdurf

  • Huifeng Yun

  • August 11, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Rheumatology
    • Vaccine Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Immunology
    • Infectious Diseases

  • #3

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Autoimmune Diseases

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Rheumatology
    • Vaccine Research

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Rheumatology
    • Immunology
    • Infectious Diseases

Original Source(s)

Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

  • by Dagna Constenla, Germain Lonnet, Emmanuel Aris, Ramsanjay Rk, Nathalie Servotte, Agnes Mwakingwe-Omari, Hannah Alsdurf, Huifeng Yun

  • August 11, 2025

Related Content

REACH: C—cause

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort